LyGenesis
PrivateLast Round
Series A
Extension
Oct 24, 2023
Total Funding Raised
$37M
Company Overview
LyGenesis operates in Healthcare & Life Sciences and is based in Pittsburgh, Pennsylvania. Its latest recorded funding round was a Series A Extension round in October 2023.
LyGenesis is a clinical-stage biotechnology company developing cell therapies that use a patient's lymph nodes as bioreactors to regrow functioning ectopic organs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LyGenesis Comparables
Compare LyGenesis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Satellite Bio | 81% | |
| Morphocell Technologies | 80% | |
| HepaTx Corporation | 80% |
For institutional investors. Book with your work email.
LyGenesis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 24, 2023 | ||||
| Convertible Debt | Dec 30, 2020 | ||||
| Convertible Debt | Oct 21, 2019 | ||||
| Series A | May 9, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
LyGenesis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longevity Vision Fund | Convertible Debt |
| Prime Movers Lab | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 16, 2026
Monthly visitors increased 78% MoM.
- Dec 30, 2020
$11M round led by Longevity Vision Fund and Juvenescence
For institutional investors. Book with your work email.
LyGenesis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about LyGenesis's valuation, stock price, and market status.
Is LyGenesis a public or private company?
LyGenesis is a private company.
What is the current stock price of LyGenesis?
LyGenesis is a private company, so its shares have no public market price. Caplight tracks LyGenesis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is LyGenesis worth (valuation)?
Valuation information for LyGenesis is not publicly available.
Can I buy LyGenesis stock?
LyGenesis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was LyGenesis's last funding round?
LyGenesis's most recent funding round was Series A Extension on October 24, 2023.
Who are the main investors in LyGenesis?
Key investors in LyGenesis include Longevity Vision Fund, Prime Movers Lab.
Will LyGenesis IPO soon?
No public IPO plans have been announced for LyGenesis.
How can I track LyGenesis secondary market activity?
Caplight tracks bids, offers, and trades in LyGenesis's shares on secondary markets.